Authors


Kathy Oubre, MS

Latest:

Biosimilars and Employers: Strategies for Success

The author, who is CEO of Pontchartrain Cancer Center, discusses how biosimilars can be part of a strategy for delivering high-quality care while achieving savings.


Denise Myshko

Latest:

CVS Caremark Switches Up Biosimilar Coverage in 2024

As new biosimilars are added to CVS Caremark’s standard formulary, others are removed. One notable change is with the Humira biosimilars: the pharmacy benefit manager has removed Amjevita in favor of Hyrimoz and an unbranded biosimilar.


Aaron Z. Savit, PhD

Latest:

Opinion: Purple Book Patent Listings Are Only a First Step

Intellectual property attorneys from Axinn discuss the limitations of the Purple Book patent disclosure requirements and the burden these impose on biosimilar developers.


Joseph Park, PhD

Latest:

Confusion Persists Around the Interchangeability Designation for Biosimilars

The legal and common uses of “interchangeability” continue to be conflated.


Gillian Woollett, MA, DPhil

Latest:

Confusion Persists Around the Interchangeability Designation for Biosimilars

The legal and common uses of “interchangeability” continue to be conflated.


Jeannette Y. Wick, RPh, MBA, FASCP

Latest:

Learning the Lingo of Biologics and Biosimilars Is Critical

The number of FDA-approved biologics has exploded, and biosimilars are making their mark.


Dan Danielson, RPh, MS

Latest:

Contributor: What’s Behind the Slow Uptake of Biosimilars in the US?

Dan Danielson, RPh, MS, senior director, market access solutions, at PrecisionValue, a market access marketing firm, explains the remaining issues at play slowing down biosimilar uptake in the United States.


Alejandro Menchaca, JD

Latest:

The Inner Workings of the BPCIA Patent Dance

The Biologics Price Competition and Innovation Act (BPCIA) provides a stepwise approach for fact-finding prior to patent litigation, but companies may choose their own path, case examples show.


Kristi Rosa

Latest:

BLA Resubmitted to FDA for On-Body Injector Presentation of Pegfilgrastim-cbqv

The biologics license application (BLA) seeking the approval of the on-body injector presentation of pegfilgrastim-cbqv, a biosimilar of Neulasta Onpro, has been resubmitted to the FDA for review.


University of Arizona R. Ken Coit College of Pharmacy

Latest:

Dr Ivo Abraham Column: Biosimilars and the Commoditization of Treatments

Ivo Abraham, PhD, chief scientist of Matrix45 and a professor at the University of Arizona, explores whether biosimilars should be considered a commodity and if the commodification of medications is sustainable as the market continues to expand.

© 2024 MJH Life Sciences

All rights reserved.